Insider · CIK 0001722234

Agger Mette Kirstine

Reports to the SEC for 4 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001722234

Forms 4 and 5

Insider transactions

27 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-25	LXEOLexeo Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+35K sh	—	—	35,000
2025-10-07	SCPHscPharmaceuticals Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−19.8K sh	—	—	0
2025-10-07	SCPHscPharmaceuticals Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−30K sh	—	—	0
2025-06-26	LXEOLexeo Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2025-06-03	SCPHscPharmaceuticals Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2024-06-25	LXEOLexeo Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+18K sh	—	—	18,000
2024-06-11	SCPHscPharmaceuticals Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+19.8K sh	—	—	19,750
2024-02-02	LXEOLexeo Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+36K sh	—	—	36,000
2023-06-06	SCPHscPharmaceuticals Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+17.3K sh	—	—	17,300
2020-06-09	SCPHscPharmaceuticals Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+6,124 sh	—	—	6,124
2020-03-16	ELVNEnliven Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+1.25M sh	—	—	1,245,222
2020-03-16	ELVNEnliven Therapeutics, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.89M sh	—	—	0
2020-03-16	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+15.5K sh	—	—	15,457
2020-03-16	ELVNEnliven Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−5.47M sh	—	—	0
2020-03-16	ELVNEnliven Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+188K sh	$16.00	+$3M	1,432,722
2020-03-16	ELVNEnliven Therapeutics, Inc. · Series Seed Preferred StockC Conversion	Director, 10% Owner	CConversion	−479K sh	—	—	0
2019-06-18	SCPHscPharmaceuticals Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+6,124 sh	—	—	6,124
2019-05-09	TRVITrevi Therapeutics, Inc.P Purchase	Director	PPurchase	+375K sh	$10.00	+$3.75M	1,151,544
2019-05-09	TRVITrevi Therapeutics, Inc. · Series C Preferred StockC Conversion	Director	CConversion	−6.85M sh	—	—	0
2019-05-09	TRVITrevi Therapeutics, Inc.C Conversion	Director	CConversion	+777K sh	—	—	776,544
2019-05-07	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23.7K sh	—	—	23,684
2018-06-19	SCPHscPharmaceuticals Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+6,124 sh	—	—	6,124
2017-11-21	SCPHscPharmaceuticals Inc. · Series A Preferred StockC Conversion	Director	CConversion	−11.1M sh	—	—	0
2017-11-21	SCPHscPharmaceuticals Inc.C Conversion	Director	CConversion	+984K sh	—	—	2,529,224
2017-11-21	SCPHscPharmaceuticals Inc. · Series B Preferred StockC Conversion	Director	CConversion	−7.07M sh	—	—	0
2017-11-21	SCPHscPharmaceuticals Inc.C Conversion	Director	CConversion	+1.54M sh	—	—	1,544,858
2017-11-21	SCPHscPharmaceuticals Inc.P Purchase	Director	PPurchase	+655K sh	$14.00	+$9.17M	3,183,986

Recent filings

Accepted (ET)
Jun 294
Agger Mette Kirstine0001722234-26-000002
SEC(opens sec.gov)
Oct 74
Agger Mette Kirstine0001193125-25-233531
SEC(opens sec.gov)
Jun 304
Agger Mette Kirstine0001415889-25-018518
SEC(opens sec.gov)
Jun 54
Agger Mette Kirstine0000950170-25-082541
SEC(opens sec.gov)
Jun 274
Agger Mette Kirstine0001415889-24-018343
SEC(opens sec.gov)
Jun 134
Agger Mette Kirstine0000950170-24-073126
SEC(opens sec.gov)
Feb 64
Agger Mette Kirstine0001209191-24-002929
SEC(opens sec.gov)
Jun 84
Agger Mette Kirstine0000899243-23-014861
SEC(opens sec.gov)
Jun 114
Agger Mette Kirstine0000899243-20-016168
SEC(opens sec.gov)
Mar 164
Agger Mette Kirstine0000899243-20-008492
SEC(opens sec.gov)
Jun 204
Agger Mette Kirstine0000899243-19-017642
SEC(opens sec.gov)
May 134
Agger Mette Kirstine0000899243-19-013253
SEC(opens sec.gov)

Companies

Address

C/O LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, FLOOR 6

NEW YORK, NY, 10010